Targeting regulator of mitochondrial cell death delivers anticancer activity
A novel anticancer molecule created by researchers showed therapeutic activity in preclinical models of various cancer types.
Read moreLeukemia
'Dietary' vulnerability found in cancer cells with mutated spliceosomes
A research team has discovered a metabolic vulnerability in multiple types of cancer cells that bear a common genetic mutation affecting cellular machines called spliceosomes.
Read moreCancer data provide insights into occurrence, overdiagnosis, and treatment advances
Investigators analyzed 40 years of cancer burden data and examined patterns of incidence and mortality for various cancers, finding examples for which incidence and mortality moved in concert and examples where discordance in incidence and mortality indicate that overdiagnosis may be at play.
Read moreMutant cells team up to make an even deadlier blood cancer
Two very different mutations have been identified as unexpected partners in crime for causing the blood cancer acute myeloid leukemia (AML). Expert analysis from CSHL helped reveal how this deadly duo is far more common in AML than thought.
Read moreA new route to blocking children's bone cancer
A study in mice showed that reducing a particular hormone signal keeps the cancer from growing and spreading.
Read moreEngineered T cells may be harnessed to kill solid tumor cells
A new study finds that a form of immunotherapy used to treat the blood cancer leukemia may be effective in treating other kinds of cancer as well.
Read moreDecades-long drop in breast cancer death rate continues
A decades-long decline in the breast cancer death rate continues, but has begun to slow in recent years.
Read moreDiscovery of new source of cancer antigens may expand cancer vaccine capabilities
Scientists have found a common, new source of tumor mutations that could offer three levels of therapy with a cancer vaccine: 1) a broadly protective, or pan-cancer vaccine 2) cancer-type specific vaccines (e.g. breast vs. pancreatic), 3) personalized cancer vaccines based on mutations unique to an individual.
Read moreFor the first time, professor observes crystallized iron product, hemozoin, made in mammals
For the first time ever, a professor has observed a crystallized iron product called hemozoin being made in mammals, with widespread implications for future research and treatment of blood disorders. Findings could be used to treat sickle cell disease and malaria patients, while opening up diverse research avenues across immunology, parasitology, neuroscience, microbiology, and even urology.
Read moreBreast cancer: New data on cohort with recurrence score 26-100 shows 93% cancer-free rate at 5 years
In the prospective TAILORx trial, 93% of women with hormone-sensitive, HER2-negative, axillary node-negative breast cancer and a high Recurrence Score 26-100 were estimated to be cancer-free at five years. This outcome was much better than expected with endocrine therapy alone. The finding adds to limited data on outcomes with a high RS of 26-100, treated with taxane and/or anthracycline-containing chemotherapy plus endocrine therapy. It adds to the body of evidence supporting use of the RS.
Read more